Sends Letter to Athira’s Shareholders Seeking Replacement of CEO Dr. Mark LittonHighlights New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to Maximize Likelihood of SuccessUrges ATHA Shareholders to VOTE the BLUE Proxy Card NEW YORK (BUSINESS WIR.